Glargine plus Lixisenatide or vildagliptin succeeding to BOT T2DM control evaluation trial in Kobe
Not Applicable
- Conditions
- T2DM
- Registration Number
- JPRN-UMIN000010769
- Lead Sponsor
- Kobe University Graduate school of medicine diabetes and endocrinology
- Brief Summary
HbA1c decreased equally, lixisenatide had the larger BW reduction effect than vildagliptin
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 48
Inclusion Criteria
Not provided
Exclusion Criteria
Renal or Liver dysfunction Pregnant or breast-feeding women Slowly progressive T1DM
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Improvement of HbA1c Improvement daily BG profile
- Secondary Outcome Measures
Name Time Method